ADVANCED HR+/HER2- BREAST CANCER
Clinical trials for ADVANCED HR+/HER2- BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ADVANCED HR+/HER2- BREAST CANCER trials appear
Sign up with your email to follow new studies for ADVANCED HR+/HER2- BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo aims to control advanced breast cancer
Disease control Recruiting nowThis study tests a new drug called GVV858, alone or with hormone therapy, in people with advanced HR+/HER2- breast cancer or other solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it can help control the disease. About 205 ad…
Matched conditions: ADVANCED HR+/HER2- BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 03:11 UTC
-
New combo therapy targets Hard-to-Treat breast cancer
Disease control Recruiting nowThis study tests a new drug called ECI830, alone or with other cancer drugs, in people with advanced hormone receptor-positive, HER2-negative breast cancer or certain solid tumors. The goal is to find safe doses and see if the combination shrinks tumors or delays growth. About 28…
Matched conditions: ADVANCED HR+/HER2- BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 03:08 UTC